tirzepatide with peptides Premium Compounded Tirzepatide: A Dual-Action Peptide
Description
The SURPASS program, the series of phase 3 trials that led to tirzepatide approval, enrolled thousands of participants across multiple studies
the FDA, EMA, etc)
These biomarkers include leptin, chitinase-3 like-protein-1 (YKL-40), growth differentiation factor 15 (GDF-15), and intercellular adhesion molecule 1 (ICAM-1)
Serious adverse reactions may include: pancreatitis, gallbladder disease, kidney injury, and severe gastrointestinal events
Harris will review history + labs)
